The main objective of this project is to assess the average cost of the treatment of bleeding
postpartum with recombinant activated factor VII (NovoSeven®) and compare it to the reference
strategy. Costs related to medicine NovoSeven® can generate surplus, but it also avoids in
some cases very costly invasive procedures. It will be interesting to compare the average
cost of the complete strategies supported.